Biotechnology company CytoDyn Inc. (CYDY.OB) announced Monday that it has enrolled and treated the first two COVID-19 patients with leronlimab under its Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications. The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.
from RTT - Biotech https://ift.tt/2V6T7j6
via IFTTT
No comments:
Post a Comment